Cambridge, Mass.-based Moderna announced that its COVID-19 vaccine candidate, mRNA-1273, demonstrated 94.5 percent efficacy in early results from a phase 3 trial.
The interim analysis, based on 95 positive COVID-19 cases, found that only five of the participants who tested positive had received the vaccine, while the other 90 positive cases were participants who had received a placebo.
The news follows Pfizer/BioNTech’s announcement last week that their vaccine candidate, BNT162b2, is more than 90 percent effective, based on interim phase 3 data.
Swiss contract drug manufacturer Lonza said it plans to produce ingredients for 400 million doses of Moderna’s vaccine per year.